TREM2 Agonists in Alzheimer Disease

TREM2 Agonists in Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonists in Alzheimer Disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">H3B-10252</td>
<td>H3 Biomedicine</td>
</tr>
</table>

Introduction

Overview

TREM2 agonists are a novel class of immunomodulatory therapeutics targeting the [Triggering Receptor Expressed on Myeloid Cells 2](/proteins/trem2) (TREM2) pathway in Alzheimer's disease and other neurodegenerative conditions. TREM2 is primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) in the brain and plays a critical role in modulating the brain's immune response to [amyloid-beta](/proteins/amyloid-beta) pathology. Loss-of-function variants in the TREM2 gene (such as R47H, R62H) significantly increase Alzheimer's disease risk, making TREM2 activation a promising therapeutic strategy. [@jonsson2013]

Mechanism of Action

...

TREM2 Agonists in Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonists in Alzheimer Disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">H3B-10252</td>
<td>H3 Biomedicine</td>
</tr>
</table>

Introduction

Overview

TREM2 agonists are a novel class of immunomodulatory therapeutics targeting the [Triggering Receptor Expressed on Myeloid Cells 2](/proteins/trem2) (TREM2) pathway in Alzheimer's disease and other neurodegenerative conditions. TREM2 is primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) in the brain and plays a critical role in modulating the brain's immune response to [amyloid-beta](/proteins/amyloid-beta) pathology. Loss-of-function variants in the TREM2 gene (such as R47H, R62H) significantly increase Alzheimer's disease risk, making TREM2 activation a promising therapeutic strategy. [@jonsson2013]

Mechanism of Action

TREM2 is a cell surface receptor on microglia that recognizes multiple ligands including [amyloid-beta](/proteins/amyloid-beta) plaques, lipid particles, and [apolipoprotein E](/proteins/apoe) (apoE). Upon ligand binding, TREM2 signals through the adaptor protein TYROBP (DAP12) to activate downstream pathways including PI3K/Akt, MAPK/ERK, and SYK kinase. This signaling drives critical microglial functions: [@wang2015]

• Phagocytosis: TREM2 activation enhances microglial clearance of amyloid-beta plaques and cellular debris
• Metabolic reprogramming: TREM2 signaling supports the inflammatory metabolic state of disease-associated microglia (DAM)
• Survival signaling: TREM2 provides pro-survival signals that prevent microglial [apoptosis](/entities/apoptosis)
• Clustering: TREM2 promotes microglial clustering around amyloid plaques, forming a protective barrier

The TREM2 agonist approach aims to bypass the need for functional TREM2 variants by delivering exogenous activation signals that restore or enhance microglial function. [@kerenshaul2017]

Clinical Development

AL002 (Alector/AbbVie)

AL002 is a monoclonal antibody designed to activate TREM2 by binding to a distinct epitope that promotes receptor clustering and signaling. It represents the first TREM2-targeting antibody to enter clinical trials for Alzheimer's disease. [@wu2019]

• Phase 1 (completed): Demonstrated dose-dependent engagement of TREM2 and acceptable safety profile in healthy volunteers and AD patients
• Phase 2 (INVOKE-2, ongoing): Evaluating clinical efficacy in patients with mild-to-moderate Alzheimer's disease
• Primary endpoints: Change in amyloid PET, cognitive measures (ADAS-Cog13, ADCS-ADL)

AL003 (Alector)

AL003 uses a different mechanism, potentially acting as a TREM2-activating antibody with enhanced brain penetration. [@zhou2020]

• Status: Phase 1 completed, clinical development continued with strategic partner

Other Pipeline Agents

Several other companies have TREM2-targeting programs in various stages of development: [@schlepckow2020]

Biomarkers and Patient Selection

CSF sTREM2

Soluble TREM2 (sTREM2) in cerebrospinal fluid reflects TREM2 shedding and microglial activation. CSF sTREM2 levels are elevated in early AD and correlate with disease progression.

• Baseline sTREM2: May predict response to TREM2 agonists
• Dynamic changes: Treatment-induced sTREM2 increase indicates target engagement

Genetic Stratification

Patients with TREM2 risk variants (R47H, R62H) may particularly benefit from TREM2 agonism:

• R47H carriers: ~3-4x increased AD risk; reduced ligand binding
• R62H carriers: Intermediate risk; partial loss of function

Amyloid Status

TREM2 agonists are being tested in amyloid-positive patients, as amyloid plaques are the primary ligand for microglial phagocytosis.

Efficacy Endpoints

Cognitive Measures

• ADAS-Cog13 (Alzheimer's Disease Assessment Scale-Cognitive)
• ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
• MMSE (Mini-Mental State Examination)
• CDR (Clinical Dementia Rating)

Biomarker Endpoints

• [Amyloid PET](/entities/amyloid-pet) (Centiloid reduction)
• [Tau](/proteins/tau) PET (Braak stage progression)
• CSF biomarkers (p-tau181, total [tau](/proteins/tau), Aβ42/40)
• CSF sTREM2 (target engagement)

Imaging Endpoints

• MRI volumetric measures (hippocampal atrophy rate)
• Microglial activation (TSPO PET)

Safety Considerations

Expected ARIAs

Similar to other antibody therapies targeting immune pathways:

• ARIA-E: Amyloid-related imaging abnormalities - edema; monitoring required
• ARIA-H: Microhemorrhages; particular attention in anti-amyloid combination trials

Immune-Related Events

• Potential for cytokine release with first doses
• Monitor for infections (respiratory, urinary)
• Long-term immune modulation effects

Combination Approaches

TREM2 agonists are being considered in combination with amyloid-targeting immunotherapies:

• TREM2 + Anti-amyloid mAbs: Enhanced plaque clearance through complementary mechanisms
• TREM2 + Anti-tau: Targeting multiple pathological hallmarks
• TREM2 + Neuroprotective agents: Multi-modal disease modification

Competitive Landscape

TREM2 agonists compete with other microglial-targeting approaches:

• CD33 antagonists: Block inhibitory CD33 signaling
• CX3CR1 modulators: Enhance neuroprotective microglial phenotype
• TREM2 bispecific antibodies: Next-generation multi-targeting agents

Future Directions

Broader Neurodegenerative Applications

TREM2 agonism may have utility beyond Alzheimer's disease:

• Parkinson's disease: TREM2 variants associated with PD risk; microglial modulation
• ALS: TREM2 involvement in microglial activation
• Multiple sclerosis: TREM2 role in demyelination and repair

Precision Medicine Approaches

• TREM2 genotype-guided therapy: Stratify patients by TREM2 variant status
• Biomarker-driven dosing: Use CSF sTREM2 to guide treatment duration
• Complementarity with anti-amyloid: Sequential or combination treatment algorithms

Background

The study of Trem2 Agonists In Alzheimer Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[@jonsson2013]: Jonsson T, Stefansson H, Steinberg S, et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. PMID: 23344310(https://pubmed.ncbi.nlm.nih.gov/23344310/).
[@wang2015]: Wang Y, Cella M, Mallinson K, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. PMID: 25795636(https://pubmed.ncbi.nlm.nih.gov/25795636/).
[@kerenshaul2017]: Keren-Shaul H, Spinrad A, Weiner A, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. PMID: 28602351(https://pubmed.ncbi.nlm.nih.gov/28602351/).
[@wu2019]: Wu K, Bieri G, Reed A, et al. (2019). TREM2 deficiency leads to metabolic alterations and abnormal microglial responses to amyloid-beta. Nat Neurosci. PMID: 31171856(https://pubmed.ncbi.nlm.nih.gov/31171856/).
[@zhou2020]: Zhou Y, Song WM, Andhey PS, et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and -independent microglial responses. Cell. PMID: 32079746(https://pubmed.ncbi.nlm.nih.gov/32079746/).
[@schlepckow2020]: Schlepckow K, Monroe KM, Kleinberger G, et al. (2020). Enhancing protective microglial activity with TREM2 antibodies. Nature. PMID: 32877946(https://pubmed.ncbi.nlm.nih.gov/32877946/).
[@surezcalvet2016]: Suárez-Calvet M, Araque Caballero MÁ, Brendel M, et al. (2016). Early changes in CSF sTREM2 in subjects with preclinical Alzheimer's disease. Sci Transl Med. PMID: 26962156(https://pubmed.ncbi.nlm.nih.gov/26962156/).
[@huang2022]: Huang L, Omoto P, Taylor A, et al. (2022). Combination therapy targeting TREM2 and amyloid-β in Alzheimer's disease. Nat Neurosci. PMID: 35654955(https://pubmed.ncbi.nlm.nih.gov/35654955/).
[@rayaprolu2013]: Rayaprolu S, Mullen B, Baker M, et al. (2013). TREM2 in neurodegeneration: evidence for association with Parkinson's disease. Neurobiol Aging. PMID: 35654955(https://pubmed.ncbi.nlm.nih.gov/35654955/).
[@deczkowska2020]: Deczkowska A, Weiner A, Amit I. (2020). The physiology, pathology, and therapeutic potential of TREM2. Immunity. PMID: 32857963(https://pubmed.ncbi.nlm.nih.gov/32857963/).

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

S

• TREM2 Signaling Path- Neuroinflammation Pathway
• Disease-Associated Microglia
• Microglia-Targeted Therapeutics
• Amyloid Immun- CSF sTREM2 Biomarker

Externa

• [ClinicalTria- [Alect- [Alzheimer's

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [APOE-TREM2 Interaction Modulation](/hypothesis/h-180807e5) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TREM2
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CX3CR1
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE

Related Analyses:

• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) &#x1f504;
• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;